This year we celebrated our one-year anniversary operating as the Autoimmune Association following our rebrand from the American Autoimmune Related Diseases Association (AARDA). With a new logo and a new name that clearly defines our focus, we strengthened our commitment to leading the fight against autoimmune disease.

Throughout 2022, we made significant progress in advocacy, awareness, education, and research. We advanced legislation at the federal and state levels to improve healthcare access and affordability, and we are leading advocacy efforts to garner congressional support for a new Office of Autoimmune Disease Research at the National Institutes of Health. We raised awareness for autoimmune disease throughout the year, with Autoimmune Awareness Month in March driving noteworthy attention. We held roundtables and conducted surveys to better understand health disparities among underrepresented populations, and we enhanced our partnerships with patient advocacy groups, the medical and research communities, and industry organizations for a collaborative approach to fulfilling our mission. As we look to the future, we embarked on the development of a new strategic plan that will inform and shape our focus for the next several years.

All of us at the Autoimmune Association are inspired by the progress we’ve made on behalf of the autoimmune community. We are committed to building upon these achievements and creating unprecedented change in the fight against autoimmune disease for years to come.

Thank you for joining us on this journey and your support.

Molly Murray
President & CEO
Our Mission

The Autoimmune Association is the world’s leading nonprofit organization dedicated to autoimmune awareness, advocacy, education, and research.

Board of Directors

Officers
- President & CEO - Molly Murray
- Chair - Lilly Stairs
- Vice Chair - Mirta Santos
- Treasurer - Linda Roelans
- Secretary - Anna Lagassie

Members
- Indie Lee
- Robert H. Phillips, Ph.D.
- Sloane Salzburg
- Scott Williams

Advisors
- Stephanie P. Hales
- Nona Bear

National Scientific Advisory Board
- Chair - Betty Diamond, M.D.

CONTACT
Autoimmune Association
19176 Hall Road, Suite 130
Clinton Township, MI 48038
United States

(586) 776-3900
autoimmune.org
hello@autoimmune.org
Major Accomplishments during Fiscal Year 2022

AWARENESS

In March, the Autoimmune Awareness Month campaign encouraged the autoimmune community to share their personal autoimmune stories. More than 50 people shared their unique and inspiring autoimmune stories that the Autoimmune Association shared across social media platforms. Additionally, autoimmune advocates shared their stories via a special Instagram reel campaign set to Imagine Dragons' hit song “Believer.” This song is about lead singer Dan Reynolds’ journey living with Ankylosing Spondylitis and how the pain he has lived through has made him the person that he is. The campaign garnered over 70,000 views.

Throughout the year, the Autoimmune Association attended and presented at several major autoimmune, biotech, and policy conferences and events. Staff collaborated with the communities to learn about the latest developments, share insights, and advocate for state and federal policies that improve healthcare access and affordability.

ADVOCACY

Let My Doctors Decide (LMDD) expanded its efforts to raise awareness about harmful access barriers and promoted meaningful solutions to ensure that treatment decisions are always made by patients and trusted health care professionals. The strategy focused on humanizing the negative implications of access barriers through highly visual and data-driven narratives via partner engagement, thought leadership, earned media, and social media engagement.

Additionally, the National Coalition of Autoimmune Patient (NCAPG) has significantly grown the past year, adding several organizations that increase representation of autoimmune disease states across the globe. The growth and impact of the NCAPG magnifies the voice of patients living with autoimmune disease and their families.

The Autoimmune Association continued to advocate for patient-first policies at the state and federal levels, particularly regarding access to care and encouraging fair and transparent insurance benefits and coverage.
The Autoimmune Association obtained a Eugene Washington PCORI Engagement Award to disseminate the Lupus Decision Making tool, designed to empower patients with unbiased information about the various side effects, risks, and benefits of the most common for lupus treatment options. The tool empowers individuals with knowledge to become their own best advocate.

In October 2021, the Autoimmune Association hosted the inaugural Autoimmune Summit, bringing together nearly 2,000 people from across the autoimmune community. The summit featured 23 educational and empowering sessions and over 50 autoimmune experts including physicians, nurses, policy experts and notable patient advocates. Discussions addressed the most pressing topics that impact patients and caregivers living with autoimmune conditions. From tips and tricks for managing multiple specialists to clinical trials, health equity, access, complementary medicine, pregnancy, and beyond. Testimonials from attendees illustrate the meaningful impact the Summit had on their journey as an autoimmune patient with many reporting that the experience left them feeling empowered with new tools for managing their condition, helped them to realize they are not alone in learning to live with autoimmune disease and that there is great hope for the future of autoimmune treatment.

The Autoimmune Association held roundtable discussions with underserved communities including women of color, males, transgender and non-binary individuals, and those who live in rural areas to help identify disparities in the diagnostic journey. Through a series of guided questions that included discussions on patient voices, cultural awareness, shared decision making and personal success, participants shared their unique journeys and the barriers they overcame to achieve a diagnosis, including the biases they encountered while engaging with the medical community. The goal is for the data and insights derived to lead to improvements inpatient experience, access to care, and future solutions resulting in positive outcomes.

The National Academies of Sciences, Engineering, and Medicine (NASEM) released a report recommending that the National Institutes of Health (NIH) create an Office of Autoimmune Disease/Autoimmunity Research. At the request of the Labor, Health and Human Services, Education subcommittee of the House Appropriations Committee, the Autoimmune Association worked with the Committee to draft report language that was included in the FY 2023 spending bill, encouraging the NIH to create the Office of Autoimmunity/Autoimmune Disease Research. The Autoimmune Association continues to offer its full support and assistance as the NIH considers its strategy.
Major Contributors

$250-$999

Emily Alter
Anonymous
Kenneth April
Jameelah Aziz
Joy Berenfield
Ed and Nancy Bettinardi
Bungie Inc.
Eileen Canavan-McCarthy and Ward McCarthy
Bonnie Canelakes
CASEY Giving Fund
Ed and Judy Christian
Effie Clayton
Cohan-Jacobs Family Fund
Ina Cohen
Comcast Corporation
Janet Craddock
Michael Deitch
Michael DeRosa
William DeRousse
Justine Devlin
Donovan Family Charitable Fund
Alice Dorn
Andrew and Maryan Dunnet
James Frieden
John Patrick & Mildred Kathryn Gilmartin Memorial Gift Fund
Connie Goetzel
Raymond Goldstein
Sheldon and Florence Gordon
Grafin Skin and Beauty
Mary Sue and John Gunzburger
Dick Hannah Motor Company

Nancy Harris
Karen and Jeffrey Hays
Mr. and Mrs. Edward Hecker
Dru and Randy Hickman
Ellen Hipsky
Patrick A. Hummel Charitable Fund
Iota Elementary School 4-H Club
Mary Johnson
Betty Jordan
Alan and Constance Kadish
Geoffrey Karyn
Suzanne Klein
Elaine Knutson
Kobishop Family Charitable Fund
Rita Konetzka
Jesse LaFlair
Cecelia Lance
Lindquist Family Charitable Fund
LKQ Community Foundation
Roger Lowen
Gail and John Maloney
Steve and Laura Martin Charitable Fund
Cameron and Kelli McPhee
Barbara Meidl
Lynn Moloney
Nancy Moore
Marsha Mormon
Kimberlea Moser
Michael and Kara Mozina
Daniel Murray
Carol Namann-Frock

Kevin Ohara
Orkand Family Foundation
William Padnos and Margery Kaye
Jinah Parker
Linda May Patterson
Pillar Patient Advocates
Renaissance Charitable Foundation
Katelyn Robinson
Kim Rodriguez
James Ryan
Salesforce.com Foundation
Sarangan Sampath
Lana and Anne Sims
Kamaljeet Singh
Jennifer Smith
Nicolette and Craig Straley
Therese Strode
Darcy Stryker
Marie Taylor
Jackie Thompson & Gene Frazer
Kathleen and Daniel Thornberry
Douglas Thorne
Alyson Tom
Alex Turner Giving Fund
Judith Vierke
Debra Vivari
Lindsay Wagner
Kenneth Weingardt
Jennifer Whipple
Carol Lynn White
Charles Wofford
Major Contributors

$1000-$4999

Judith Bellin
Belovsky Family Foundation
By Mildred M. Belovsky
Ann Brouse
Cars For Charity
Clinical Outcomes Solutions
Mr. & Mrs. Nicholas Cullen
Jeffrey Davenhall
Robert and Eleanor Demple
Family Foundation
Fiber Arts Community Fundraiser
Akiva Flesher
Timothy and Wendy Foliano
Frank Futcher
Anne Hammell
Immunovant, Inc.
Deanna Irving
Keith's Appliances
Mary Kimball
David Kitchin
Virginia Ladd
Casaundra Lindsey
Dr. Nat and Jill Linhardt
Theodore & Karin Mayer Family Foundation
McCollister's Global Services Inc.
Monthly Awareness Program
Miles For Matt Hershey
James and Christine Miller Charitable Fund
The Barrie Momoda Family Fund
The Diane E. Moss Giving Fund
Elizabeth Niemeyer
One Night For Change Fundraiser
William and Tammy Pavilonis
James and Rita Peterson
Caleb Powers
Purple Butterfly Gift Fund
William and Terry Reid
Steven Robinson
The Robinson Family Charitable Fund
Jeanne Russell
Mirta Avila Santos
SetPoint Medical Corporation
Lilly Stairs
Curtis R. & Melliss K. Swenson
Vicki Tolari
Videri Chocolate Factory
Robert A. Waller Foundation
Barbara and John Wehling
Brian Williams

$5000-$19,999

ANI Pharmaceuticals, Inc.
Aurinia Pharma U.S.
Biotechnology Innovation Organization
Casey Nolan Fundraiser
Great Lakes Center of Rheumatology
Koch Family Charitable Fund
Leapcure
Mymee Inc.
Priovant Therapeutics
Thomas Tocalis Charitable Gift Fund

$20,000+

AbbVie Inc.
Alexion Pharmaceuticals Inc.
Amgen USA
Bristol-Myers Squibb Company
Eli Lilly and Company
EMD Serono, Inc.
Facebook Fundraisers
Genentech, Inc.
Genzyme, a Sanofi Company
Horizon Therapeutics
Johnson & Johnson
Health Care Systems
Mallinckrodt Pharmaceuticals
Merck & Co.
Organon
Patient-Centered Outcomes Research Institute (PCORI)
Pfizer, Inc.
PhRMA
Sandoz Inc.
Takeda Pharmaceuticals USA, Inc.
Major Contributors

Major In-Kind Contributors

BIO Convention
Context Strategies

CSRO Conference

imd Health
Sidley Austin LLP

Payroll Campaigns, Matching Gifts & Online Giving

Abbott Laboratories
AbbVie
Alaskan Airlines
Allstate
American Express
America’s Charities
AMFAM
Applied Materials Foundation
AT & T Employee Giving Campaign
BAE
Bank of America
Charities Aid Foundation of America
Charityvest Inc.
Daily Karma Foundation
Ever Loved
FINRA
Frontstream

GE Foundation
Give Lively Foundation Inc.
Google
Halliburton
IBM Employee Services Center
Jackson National Life
Kaiser Permanente
Kroger Community Rewards Program
Liberty Mutual
Microsoft
Morgan Stanley
My Tribute Gift
Network for Good
Nuance
OneHope Foundation
Open Society Institute
Paypal Giving Fund

Pfizer
Pinkaloo
Pledgeling Foundation
Regeneron
Renaissance Charitable Foundation
Shell Oil Company Foundation
Splunk
The Blackbaud Giving Fund
Trustees of American Express Foundation
U.S. Bank Foundation
UMB
United Way of Allegheny County
United Way of Central New Mexico
USAA
Visa
Auditor’s Report

The Board of Directors
American Autoimmune Related Diseases Association
Clinton Township, Michigan

OPINION

We have audited the accompanying financial statements of American Autoimmune Related Diseases Association (a nonprofit organization) which comprise the statement of financial position as of September 30, 2022, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements. In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of American Autoimmune Related Diseases Association and the related entities as of September 30, 2022 and 2021, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

BASIS FOR OPINION

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of American Autoimmune Related Diseases Association and the related entities and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

RESPONSIBILITIES OF MANAGEMENT FOR THE FINANCIAL STATEMENTS

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt American Autoimmune Related Diseases Association’s ability to continue as a going concern for one year after the date that the financial statements are issued.
AUDITOR’S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

• Exercise professional judgment and maintain professional skepticism throughout the audit.

• Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of American Autoimmune Related Diseases Association’s internal control. Accordingly, no such opinion is expressed.

• Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.

• Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about American Autoimmune Related Diseases Association’s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control—related matters that we identified during the audit.

Gordon Advising, P.C.
April 6, 2023
## Financial Statements

### For the Year Ended September 30, 2022

<table>
<thead>
<tr>
<th>Revenue and Other Support</th>
<th>WITHOUT DONOR RESTRICTIONS</th>
<th>WITH DONOR RESTRICTIONS</th>
<th>2022 TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$ 689,070</td>
<td>$ 1,008,374</td>
<td>$ 1,697,444</td>
</tr>
<tr>
<td>APC Membership Dues</td>
<td>705,500</td>
<td>0</td>
<td>705,500</td>
</tr>
<tr>
<td>In-kind goods and services</td>
<td>337,135</td>
<td>0</td>
<td>337,135</td>
</tr>
<tr>
<td>Other income</td>
<td>4,740</td>
<td>0</td>
<td>4,740</td>
</tr>
<tr>
<td>Interest income</td>
<td>1,986</td>
<td>0</td>
<td>1,986</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,738,431</strong></td>
<td><strong>1,008,374</strong></td>
<td><strong>2,746,805</strong></td>
</tr>
</tbody>
</table>

| New assets released from restrictions | 1,074,423 | (1,074,423) | 0 |

| **Total Revenue and Other Support** | 2,812,854 | (66,049)   | 2,746,805 |

### Expenses

<table>
<thead>
<tr>
<th>Program Services</th>
<th>WITHOUT DONOR RESTRICTIONS</th>
<th>WITH DONOR RESTRICTIONS</th>
<th>2022 TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education</td>
<td>1,202,687</td>
<td>0</td>
<td>1,202,687</td>
</tr>
<tr>
<td>Public Awareness</td>
<td>834,990</td>
<td>0</td>
<td>834,990</td>
</tr>
<tr>
<td>Research</td>
<td>257,958</td>
<td>0</td>
<td>257,958</td>
</tr>
<tr>
<td><strong>Total Program Services</strong></td>
<td><strong>2,295,635</strong></td>
<td><strong>0</strong></td>
<td><strong>2,295,635</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Supporting Services</th>
<th>WITHOUT DONOR RESTRICTIONS</th>
<th>WITH DONOR RESTRICTIONS</th>
<th>2022 TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and General</td>
<td>103,407</td>
<td>0</td>
<td>103,407</td>
</tr>
<tr>
<td>Fundraising</td>
<td>48,471</td>
<td>0</td>
<td>48,471</td>
</tr>
<tr>
<td><strong>Total Supporting Services</strong></td>
<td><strong>151,878</strong></td>
<td><strong>0</strong></td>
<td><strong>151,878</strong></td>
</tr>
</tbody>
</table>

| **Total Expenses** | 2,447,513 | 0 | 2,447,513 |

| Change in Net Assets | 365,341 | (66,049) | 299,292 |

### Net Assets

<table>
<thead>
<tr>
<th>Net Assets, Beginning of Year</th>
<th>WITHOUT DONOR RESTRICTIONS</th>
<th>WITH DONOR RESTRICTIONS</th>
<th>2022 TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,216,999</td>
<td>411,986</td>
<td>1,628,985</td>
<td></td>
</tr>
</tbody>
</table>

| Net Assets, End of Year      | $1,582,340               | $345,937               | $1,928,277 |


## Financial Statements

For the Year Ended September 30, 2022

<table>
<thead>
<tr>
<th></th>
<th>Education</th>
<th>Public Awareness</th>
<th>Research</th>
<th>Total Program Services</th>
<th>Management and General</th>
<th>Fundraising</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wages</td>
<td>$372,394</td>
<td>$333,225</td>
<td>$147,150</td>
<td>$852,769</td>
<td>$28,953</td>
<td>$15,622</td>
<td>$897,344</td>
</tr>
<tr>
<td>Professional Fees</td>
<td>75,944</td>
<td>49,454</td>
<td>21,226</td>
<td>146,624</td>
<td>16,340</td>
<td>8,250</td>
<td>171,214</td>
</tr>
<tr>
<td>Postage and Shipping</td>
<td>1,683</td>
<td>1,589</td>
<td>1</td>
<td>3,273</td>
<td>561</td>
<td>1,352</td>
<td>5,186</td>
</tr>
<tr>
<td>Public Relations</td>
<td>220,410</td>
<td>240,410</td>
<td>0</td>
<td>460,820</td>
<td>0</td>
<td>0</td>
<td>460,820</td>
</tr>
<tr>
<td>Legal</td>
<td>27,728</td>
<td>12,323</td>
<td>12,323</td>
<td>52,374</td>
<td>12,948</td>
<td>0</td>
<td>65,322</td>
</tr>
<tr>
<td>Consulting Services</td>
<td>82,473</td>
<td>18,658</td>
<td>14,392</td>
<td>115,523</td>
<td>6,000</td>
<td>6,850</td>
<td>128,373</td>
</tr>
<tr>
<td>Grant Writing</td>
<td>4,805</td>
<td>676</td>
<td>155</td>
<td>5,636</td>
<td>0</td>
<td>0</td>
<td>5,636</td>
</tr>
<tr>
<td>Printing and Stationary</td>
<td>2,461</td>
<td>2,359</td>
<td>51</td>
<td>4,871</td>
<td>140</td>
<td>567</td>
<td>5,578</td>
</tr>
<tr>
<td>Office Supplies</td>
<td>847</td>
<td>838</td>
<td>0</td>
<td>1,685</td>
<td>71</td>
<td>46</td>
<td>1,802</td>
</tr>
<tr>
<td>Operating Supplies</td>
<td>863</td>
<td>6,129</td>
<td>20</td>
<td>7,012</td>
<td>34</td>
<td>20</td>
<td>7,066</td>
</tr>
<tr>
<td>Dues and Subscriptions</td>
<td>30,193</td>
<td>31,978</td>
<td>17,376</td>
<td>79,547</td>
<td>2,893</td>
<td>1,401</td>
<td>83,841</td>
</tr>
<tr>
<td>Filing Fees</td>
<td>1,197</td>
<td>1,197</td>
<td>0</td>
<td>2,394</td>
<td>1,229</td>
<td>1,197</td>
<td>4,820</td>
</tr>
<tr>
<td>Planned Giving</td>
<td>875</td>
<td>875</td>
<td>0</td>
<td>1,750</td>
<td>875</td>
<td>875</td>
<td>3,500</td>
</tr>
<tr>
<td>Rent</td>
<td>24,896</td>
<td>24,896</td>
<td>0</td>
<td>49,792</td>
<td>2,119</td>
<td>1,059</td>
<td>52,970</td>
</tr>
<tr>
<td>Equipment Maintenance</td>
<td>5,688</td>
<td>3,620</td>
<td>0</td>
<td>9,308</td>
<td>517</td>
<td>517</td>
<td>10,342</td>
</tr>
<tr>
<td>Telephone</td>
<td>3,779</td>
<td>3,910</td>
<td>563</td>
<td>8,252</td>
<td>315</td>
<td>225</td>
<td>8,792</td>
</tr>
<tr>
<td>Insurance</td>
<td>1,599</td>
<td>1,599</td>
<td>0</td>
<td>3,198</td>
<td>1,599</td>
<td>1,599</td>
<td>6,396</td>
</tr>
<tr>
<td>State and Nat'l Meetings</td>
<td>11,987</td>
<td>14,763</td>
<td>5,560</td>
<td>32,310</td>
<td>2,357</td>
<td>1,743</td>
<td>36,410</td>
</tr>
<tr>
<td>Travel</td>
<td>3,907</td>
<td>7,159</td>
<td>3,440</td>
<td>14,506</td>
<td>1,689</td>
<td>966</td>
<td>17,161</td>
</tr>
<tr>
<td>Depreciation</td>
<td>1,372</td>
<td>1,372</td>
<td>1,372</td>
<td>4,116</td>
<td>1,372</td>
<td>1,372</td>
<td>6,860</td>
</tr>
<tr>
<td>Payroll Taxes</td>
<td>25,131</td>
<td>32,311</td>
<td>10,770</td>
<td>68,212</td>
<td>2,154</td>
<td>1,436</td>
<td>71,802</td>
</tr>
<tr>
<td>Insurance - Health</td>
<td>24,685</td>
<td>23,968</td>
<td>8,345</td>
<td>56,998</td>
<td>2,763</td>
<td>1,351</td>
<td>61,112</td>
</tr>
<tr>
<td>Board Expenses</td>
<td>71</td>
<td>71</td>
<td>0</td>
<td>142</td>
<td>12,529</td>
<td>0</td>
<td>12,671</td>
</tr>
<tr>
<td>Honorariums</td>
<td>14,346</td>
<td>1,565</td>
<td>2,396</td>
<td>18,307</td>
<td>90</td>
<td>190</td>
<td>18,587</td>
</tr>
<tr>
<td>Professional Training</td>
<td>399</td>
<td>367</td>
<td>300</td>
<td>1,066</td>
<td>1,210</td>
<td>52</td>
<td>2,328</td>
</tr>
<tr>
<td>Grants</td>
<td>0</td>
<td>0</td>
<td>5,000</td>
<td>5,000</td>
<td>0</td>
<td>0</td>
<td>5,000</td>
</tr>
<tr>
<td>Repairs and Maintenance</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Utilities</td>
<td>1,116</td>
<td>1,116</td>
<td>0</td>
<td>2,232</td>
<td>95</td>
<td>48</td>
<td>2,375</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>108</td>
<td>95</td>
<td>91</td>
<td>294</td>
<td>1,032</td>
<td>85</td>
<td>1,141</td>
</tr>
<tr>
<td>Retirement Plan Contributions</td>
<td>7,320</td>
<td>12,808</td>
<td>7,419</td>
<td>27,547</td>
<td>1,278</td>
<td>1,204</td>
<td>30,029</td>
</tr>
<tr>
<td>Website</td>
<td>252,335</td>
<td>5,659</td>
<td>8</td>
<td>258,002</td>
<td>432</td>
<td>444</td>
<td>258,878</td>
</tr>
<tr>
<td>Advertising and Development</td>
<td>2,075</td>
<td>0</td>
<td>0</td>
<td>2,075</td>
<td>1,812</td>
<td>0</td>
<td>3,887</td>
</tr>
</tbody>
</table>

**Total Expenses by Function**

<table>
<thead>
<tr>
<th></th>
<th>$1,202,687</th>
<th>$834,990</th>
<th>$257,958</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wages</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professional Fees</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postage and Shipping</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public Relations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Legal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consulting Services</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grant Writing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Printing and Stationary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Office Supplies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating Supplies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dues and Subscriptions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filing Fees</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Planned Giving</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rent</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equipment Maintenance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telephone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insurance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>State and Nat'l Meetings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Travel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payroll Taxes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insurance - Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Board Expenses</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Honorariums</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professional Training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Repairs and Maintenance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Utilities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retirement Plan Contributions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advertising and Development</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Less expenses included with revenues on the statement of activities

|                      | $0         | $0        | $0        |

**Total expenses included in the expense section on the statement of activities**

<table>
<thead>
<tr>
<th></th>
<th>$1,202,687</th>
<th>$834,990</th>
<th>$257,958</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wages</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professional Fees</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postage and Shipping</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public Relations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Legal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consulting Services</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grant Writing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Printing and Stationary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Office Supplies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating Supplies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dues and Subscriptions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filing Fees</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Planned Giving</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rent</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equipment Maintenance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telephone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insurance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>State and Nat'l Meetings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Travel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payroll Taxes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insurance - Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Board Expenses</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Honorariums</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professional Training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Repairs and Maintenance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Utilities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retirement Plan Contributions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advertising and Development</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>